OrbiMed

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Aerin Medical is a health technology company that develops non-invasive therapeutic devices to improve nasal breathing. Its portfolio includes VivAer for nasal airway obstruction and RhinAer for chronic rhinitis, along with VivAer Stylus and RhinAer Stylus, plus a compact console that delivers temperature-controlled radiofrequency energy to remodel nasal soft tissue. The technology targets the underlying causes of nasal congestion and offers alternatives to invasive surgery. The company, founded in 2011, is based in Sunnyvale, California.

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

TriSalus Life Sciences specializes in developing precision infusion systems for interventional radiology, focusing on targeted drug delivery to treat liver cancer and other solid tumors. The company's flagship products include the Surefire precision infusion systems designed for lobar, segmental, and super-selective infusions, as well as guiding catheters. TriSalus also develops Pressure Enabled Drug Delivery (PEDD) infusion systems and investigational agents like nelitolimod to enhance immune response in cancer treatment.

Shenluo Medical manufactures functional neural implantable medical devices.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs to treat human diseases. Its pipeline includes candidates for irritable bowel syndrome, type 2 diabetes, rheumatoid arthritis, carcinoid syndrome, and glaucoma. The company has collaborations with major pharmaceutical companies and other organizations.

Arcatron Mobility is an Indian medical device startup that designs and sells mobility devices to improve independence for people with limited mobility. Focused on addressing the needs of India's aging and mobility-impaired population, the company aims to provide high-quality, affordable mobility solutions for daily living activities such as bathing and walking. By developing innovative devices, Arcatron seeks to empower users to perform daily tasks more safely and maintain autonomy, positioning itself as a trusted brand in the Indian medical device market.

Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

Koya Medical, Inc. is a healthcare company based in Oakland, California, founded in 2018. The company specializes in developing innovative wearable therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. Koya Medical's technology offers active compression therapy that enhances mobility and personalized care, addressing limitations commonly associated with traditional compression methods. Its sensor-based closed-loop system provides patient-specific patterned compression, enabling healthcare providers to effectively manage conditions like chronic edema and chronic venous insufficiency. Through its breakthrough treatments, Koya Medical seeks to transform the standard of care for individuals affected by these debilitating conditions.

InspireMD, Inc. is a medical device company based in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology aimed at treating vascular and coronary diseases. The company offers two primary products: the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, used in patients with acute coronary syndromes and saphenous vein graft interventions. InspireMD is also working on the NGuard neurovascular flow diverter, which aims to divert blood flow from cerebral aneurysms to enhance patient outcomes. The company's products are marketed through local distributors in various regions, including Europe, Latin America, the Middle East, and Asia.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Caris Life Sciences specializes in advanced molecular profiling technologies for cancer diagnostics and drug development. Established in 1987, it offers prognostic testing services, genomic profiling, and clinico-genomic data platforms to improve patient outcomes. The company operates globally with offices in the US and Switzerland.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Adaptive Biotechnologies Corporation is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system to enhance disease diagnosis and treatment. Established in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including its FDA-authorized clonoSEQ diagnostic test, which is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers, such as multiple myeloma and chronic lymphocytic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies provides immunoSEQ research services and kits to support scientific research and the discovery of new diagnostic signals. The company also has a pipeline of clinical products aimed at diagnosing and managing various diseases, including cancers, autoimmune disorders, and infectious diseases. It maintains strategic collaborations with notable partners such as Genentech and Microsoft to develop innovative therapies and diagnostic tests.

LifeWell is a new entity formed through the merger of LifeCell’s diagnostics business and MFine.

Aerin Medical is a health technology company that develops non-invasive therapeutic devices to improve nasal breathing. Its portfolio includes VivAer for nasal airway obstruction and RhinAer for chronic rhinitis, along with VivAer Stylus and RhinAer Stylus, plus a compact console that delivers temperature-controlled radiofrequency energy to remodel nasal soft tissue. The technology targets the underlying causes of nasal congestion and offers alternatives to invasive surgery. The company, founded in 2011, is based in Sunnyvale, California.

DarioHealth is a digital health company that develops and commercializes patented and proprietary technology enabling smartphone-based laboratory testing and real-time diabetes management. Its flagship Dario system combines a mobile software application with a pocket-sized blood glucose monitoring device, backed by the DarioEngage platform that provides coaching, digital communications, alerts, trend analysis, and support for chronic illness management. The company markets its solutions directly to consumers and through retail pharmacies, hospitals, and distributors across international markets, with sales occurring online as well. DarioHealth operates at the intersection of life sciences, behavioral science, and software, delivering digital therapeutics-style interventions that are personalized and data-driven across diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health through a suite of software, devices, and coaching services. Established in 2011 and headquartered in Israel, DarioHealth focuses on transforming self-management of chronic conditions by integrating software, monitoring hardware, and remote coaching.

Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.

Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.

Humacyte specializes in developing human tissue-based products for regenerative medicine and vascular surgery. It creates acellular extracellular matrices using banked vascular smooth muscle cells, which are then decellularized to eliminate rejection risks. These matrices serve as off-the-shelf tissue-engineered grafts for patients requiring vascular repair or replacement.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

Rimag is a Shenzhen‑based medical imaging service provider that operates a network of imaging centers offering MRI, CT, PET, X‑ray, ultrasound and mammography. The company also develops cloud‑based imaging solutions and provides training for medical imaging professionals. Its revenue is primarily derived from the operation of imaging centers, while additional income comes from imaging solution services and cloud services.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Owlet Baby Care Inc. is a company based in Lehi, Utah, founded in 2012, that specializes in the development and manufacturing of innovative monitoring solutions for infants. Its flagship product, the Owlet Smart Sock, is a proactive health monitor that tracks a baby's heart rate and oxygen levels while sleeping, sending alerts to parents if any concerning changes occur. The company also offers the Owlet Cam, which transforms smartphones into high-definition baby monitors, and the Owlet Monitor Duo, which combines the features of both the Smart Sock and the Cam. Additionally, Owlet provides the Owlet Dream Lab, an online program aimed at helping parents cultivate healthy sleep habits for their infants. By offering real-time data and insights, Owlet Baby Care aims to enhance parental confidence and peace of mind regarding their child's health and well-being.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Caris Life Sciences specializes in advanced molecular profiling technologies for cancer diagnostics and drug development. Established in 1987, it offers prognostic testing services, genomic profiling, and clinico-genomic data platforms to improve patient outcomes. The company operates globally with offices in the US and Switzerland.

EDDA Technology specializes in computer-assisted solutions for patient care management, particularly in the realm of imaging-guided cancer treatment. The company has developed the IQQA platform, which provides innovative imaging technologies that enhance workflow and patient care in surgical settings, including open, minimally invasive, and robotic surgeries. This platform supports a patient-specific and disease-targeted approach, facilitating a multidisciplinary strategy for cancer treatment. It encompasses the entire surgical process, offering features for pre-surgical planning and simulation, intra-operative guidance and monitoring, as well as post-operative follow-up evaluations and training. EDDA Technology's advancements aim to improve the efficiency and effectiveness of medical imaging and treatment protocols for healthcare professionals.

NewMed Medical is a Shanghai-based medical device supplier specializing in interventional artificial heart valve systems. Founded in 2015, the company focuses on researching, developing, manufacturing, and marketing products that include artificial heart valves and transcatheter implantation systems. These products are designed to replace diseased mitral valves, simplifying heart valve replacement surgeries, reducing treatment risks, and enabling faster patient recovery while saving surgery expenses.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

AnchorDx is a biotechnology company specializing in next-generation sequencing techniques, particularly through the use of molecular liquid biopsies. This innovative approach allows for non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and better prepare for potential health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to lead in precision medicine by developing comprehensive clinical applications and research platforms. The company fosters collaborations with various stakeholders, including hospitals, research institutes, and third-party testing agencies, to create a complete industrial chain that facilitates the transformation of academic research into clinical products. Through its commitment to developing independent intellectual property and competitive clinical testing solutions, AnchorDx provides accurate and comprehensive services to patients, healthcare providers, and medical institutions.

Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.

Founded in Hangzhou, China in 2012 by experienced professionals from leading global device makers, Zylox specializes in developing and distributing high-quality interventional and implantable peripheral vascular devices. Its product portfolio includes PTA balloons, drug-coated balloons, SFA stents, and other vascular accessories, aiming to improve patient outcomes worldwide.

Caris Life Sciences specializes in advanced molecular profiling technologies for cancer diagnostics and drug development. Established in 1987, it offers prognostic testing services, genomic profiling, and clinico-genomic data platforms to improve patient outcomes. The company operates globally with offices in the US and Switzerland.

Nuvation Bio is a global biopharmaceutical company dedicated to developing innovative therapies for oncology, focusing on patients with difficult-to-treat cancers where conventional treatments have proven ineffective.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

CoreMap, Inc. is a medical technology company based in Winooski, Vermont, focused on developing advanced diagnostic solutions for electrophysiologists treating atrial fibrillation. Incorporated in 2016, the company offers a micro-electrode solution that allows for sequential mapping of tissue properties, addressing significant challenges in the treatment of atrial fibrillation, such as poor spatial resolution and inadequate sample density. Additionally, CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even during episodes of fibrillation. By enhancing the diagnostic capabilities of electrophysiologists, CoreMap aims to improve patient outcomes in the management of this complex condition.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for patients undergoing organ or cellular transplantation and those with autoimmune and neurodegenerative diseases. Its lead compound, tegoprubart, is an anti-CD40L antibody targeting the CD40L pathway.

NeuroPace designs and markets implantable neuromodulation systems for neurological disorders, with a focus on epilepsy. Its flagship RNS System includes an implantable neurostimulator connected to depth and cortical leads that monitor brain activity and deliver targeted, responsive electrical stimulation to seizure onset regions. External components, including a programmer and software, enable device configuration and monitoring. Founded in 1997 and based in Mountain View, California, the company generates most revenue from selling RNS Systems to hospital facilities for implantation in patients with medically refractory partial epilepsy. NeuroPace aims to reduce or eliminate seizures through adaptive neuromodulation.

Erasca is a clinical-stage precision oncology company dedicated to discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company's pipeline includes Naporafenib, ERAS-007, and ERAS-601, targeting various nodes of this pathway.

Aerin Medical is a health technology company that develops non-invasive therapeutic devices to improve nasal breathing. Its portfolio includes VivAer for nasal airway obstruction and RhinAer for chronic rhinitis, along with VivAer Stylus and RhinAer Stylus, plus a compact console that delivers temperature-controlled radiofrequency energy to remodel nasal soft tissue. The technology targets the underlying causes of nasal congestion and offers alternatives to invasive surgery. The company, founded in 2011, is based in Sunnyvale, California.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

MabPlex International Ltd is a contract development and manufacturing organization specializing in biopharmaceuticals, including monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and bispecifics. Founded in 2013, the company operates from its headquarters in Yantai, China, and has an additional office in Fremont, California. MabPlex provides a comprehensive range of services that encompass all stages of drug development, from DNA to finished drug products. Its offerings include customized mammalian cell medium, cell banking, and the manufacturing of monoclonal antibody active pharmaceutical ingredients, as well as fill and finish services for biologics and antibody-drug conjugates. The company aims to deliver high-quality solutions for bio-manufacturing to its global partners.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

Remegen is a Chinese biopharmaceutical company focused on developing novel biologics, primarily monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), to address unmet medical needs in life-threatening conditions. Headquartered in Yantai with labs/offices in Beijing and California, Remegen's portfolio includes Telitacicept for systemic lupus erythematosus and Disitamab Vedotin for various cancers.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

NewMed Medical is a Shanghai-based medical device supplier specializing in interventional artificial heart valve systems. Founded in 2015, the company focuses on researching, developing, manufacturing, and marketing products that include artificial heart valves and transcatheter implantation systems. These products are designed to replace diseased mitral valves, simplifying heart valve replacement surgeries, reducing treatment risks, and enabling faster patient recovery while saving surgery expenses.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Apollomics is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies that harness the immune system and target specific cancer signaling pathways. Founded in 2016 and headquartered in Foster City, California, the company develops monoclonal antibodies and targeted small molecules aimed at immune checkpoints and dysregulated growth pathways, with a portfolio that includes anti-PD-1 and anti-PD-L1 antibodies and inhibitors affecting EMT and MAPK signaling. Apollomics aims to advance monotherapy and combination regimens designed to enhance anti-tumor immune responses and inhibit tumor growth.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

SmartZyme Biopharma is a medical technology company focused on enhancing continuous glucose monitoring (CGM) for individuals with diabetes. It specializes in integrating its next-generation glucose-sensing enzyme into CGM devices, aiming to improve performance, safety, and user experience. Unlike traditional methods, SmartZyme's enzyme eliminates the need for signal mediators, reducing manufacturing costs; minimizes hypoglycemic errors, ensuring superior safety; and eliminates fingersticks, enhancing quality of life. The company is backed by OrbiMed, a leading healthcare investment firm.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

TELA Bio is a medical technology company specializing in soft tissue reconstruction. It designs, develops, and markets the OviTex Reinforced Tissue Matrix portfolio for hernia repair and abdominal wall reconstruction, as well as OviTex PR Reinforced Tissue Matrix for plastic and reconstructive surgery and OviTex for laparoscopic and robotic procedures. The reinforced matrices are derived from ovine rumen with polypropylene fiber and are intended to address unmet needs in soft tissue repair while emphasizing preservation of anatomy and minimizing long-term exposure to permanent synthetic materials. The company markets its products through a single direct sales force, principally in the United States. Founded in 2012 and headquartered in Malvern, Pennsylvania.

NeuroPace designs and markets implantable neuromodulation systems for neurological disorders, with a focus on epilepsy. Its flagship RNS System includes an implantable neurostimulator connected to depth and cortical leads that monitor brain activity and deliver targeted, responsive electrical stimulation to seizure onset regions. External components, including a programmer and software, enable device configuration and monitoring. Founded in 1997 and based in Mountain View, California, the company generates most revenue from selling RNS Systems to hospital facilities for implantation in patients with medically refractory partial epilepsy. NeuroPace aims to reduce or eliminate seizures through adaptive neuromodulation.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

Xtant Medical develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons worldwide. Its portfolio includes biomaterial products like OsteoSponge, OsteoSelect Plus DBM Putty, and 3Demin allografts, along with spinal implant systems such as Certex, Spider, Axle, and Fortex. The company's offerings facilitate spinal fusion in complex spine procedures.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

Augmedix is a technology company that provides AI-powered medical documentation solutions for healthcare systems. Its platform converts natural clinician-patient conversations into real-time medical notes, organized data, and point-of-care notifications, which are transferred into electronic health records. The cloud-based system, complemented by remote medical scribes, reduces EHR documentation time and administrative burden, enabling clinicians to focus more on patient care. Augmedix serves hospitals and health systems, and has built partnerships across care settings. The company was founded in 2012 and is based in San Francisco, with offices in Menlo Park and Dhaka. The platform is available to clinicians via mobile apps and integrates ambient AI, data, and trusted workflows to improve clinical, operational, and financial outcomes.

Suraksha Diagnostics is a diagnostic services company founded in 1992 in Kolkata as Suraksha Diagnostics and Eye Centre. It was among the first centers to offer pathology and radiology under one roof, delivering integrated testing and medical consultation. The company rapidly expanded, opening a second center in Siliguri within three years, the largest facility in the region, serving North Bengal and neighboring states. It has since grown across West Bengal, Bihar, Assam, Meghalaya, and Delhi NCR, building a network that includes a flagship central reference laboratory, satellite laboratories, and diagnostic centers with sample collection points to broaden access to pathology and radiology services for patients and clinicians.

Apollomics is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies that harness the immune system and target specific cancer signaling pathways. Founded in 2016 and headquartered in Foster City, California, the company develops monoclonal antibodies and targeted small molecules aimed at immune checkpoints and dysregulated growth pathways, with a portfolio that includes anti-PD-1 and anti-PD-L1 antibodies and inhibitors affecting EMT and MAPK signaling. Apollomics aims to advance monotherapy and combination regimens designed to enhance anti-tumor immune responses and inhibit tumor growth.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Response Biomedical Corp. is a Vancouver-based company that specializes in the research, development, commercialization, and distribution of diagnostic technologies. The company focuses on rapid on-site diagnostic tests for medical central-lab testing, point of care (POC) testing, and environmental testing markets. Its primary product is the RAMP system, a portable fluorescence immunoassay-based diagnostic platform that delivers laboratory-quality results quickly and conveniently through various formats, including hand-held devices and single-use test cartridges. Response Biomedical's tests are designed for early detection of conditions such as heart attacks, congestive heart failure, and influenza, as well as environmental threats like the West Nile Virus and biodefense applications for detecting agents such as anthrax and ricin. The company distributes its products globally, targeting markets in the United States, Asia, Latin and South America, Europe, the Middle East, and Canada. Founded in 1980, Response Biomedical is committed to improving patient management in acute care settings through efficient and rapid diagnostic solutions.

Iovance Biotherapeutics is a clinical-stage biotechnology company based in San Carlos, California, specializing in the development and commercialization of cancer immunotherapy products that utilize the immune system to target and eliminate cancer cells. The company's primary focus is on tumor-infiltrating lymphocyte (TIL) therapies, with its lead candidates, lifileucel and LN-145, currently undergoing Phase II clinical trials for metastatic melanoma and metastatic cervical cancer, respectively. Iovance is also exploring additional applications of TIL and peripheral blood lymphocyte therapies for various cancers, including squamous cell carcinoma of the head and neck and chronic lymphocytic leukemia, through sponsored trials and collaborative efforts with notable research institutions. Established in 2007, Iovance aims to become a leader in the innovation and delivery of TIL therapies for solid tumors, actively preparing for potential regulatory approvals and market entry in the United States.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

UPPER is a biomedicine manufacturing firm. They provide a maya fluoresence analyzer, an ottoman automatic protein analyzer, and other products. Upper Biotech Pharma markets its products.

Eurolife Healthcare is a manufacturer and distributor of a diverse array of healthcare formulations tailored for various medical applications. The company specializes in producing generic pharmaceutical products, including intravenous infusions, ophthalmic solutions, sterilized water for injections, tablets, capsules, ointments, creams, and other formulations. Eurolife Healthcare emphasizes high-quality and sterile packaging to ensure that healthcare providers can effectively meet medical supply demands. Its product offerings extend to systems such as the eurohead infusion system, classic infusion therapy, and specialized solutions like Lifeflow and Germkill, designed to address specific therapeutic needs in the healthcare sector.

Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

SmartZyme Biopharma is a medical technology company focused on enhancing continuous glucose monitoring (CGM) for individuals with diabetes. It specializes in integrating its next-generation glucose-sensing enzyme into CGM devices, aiming to improve performance, safety, and user experience. Unlike traditional methods, SmartZyme's enzyme eliminates the need for signal mediators, reducing manufacturing costs; minimizes hypoglycemic errors, ensuring superior safety; and eliminates fingersticks, enhancing quality of life. The company is backed by OrbiMed, a leading healthcare investment firm.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Laxmi Dental is a comprehensive dental products company offering a wide range of solutions for dental laboratories and offices. Their product portfolio includes metal-free restorations, porcelain-fused-to-metal crowns and bridges, implant prosthetics, removable appliances, aligners, and pediatric dental products.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

MID Labs was founded by Dr. Carl Wang in 1981 and has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, it has been instrumental in revolutionizing the ophthalmic field through its products. MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.

Unilife is a U.S.-based medical device and technology company specializing in the design, development, manufacturing, and supply of innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that offers smart, reusable auto injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies that come in standard prefilled barrels, thereby supporting pharmaceutical and biotechnology companies in providing injectable biologics, drugs, and vaccine products. Through its focus on differentiated delivery systems, Unilife aims to improve patient experiences and outcomes in drug administration.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

Medigus is a medical device company that develops, produces, and markets minimally invasive endoscopic tools and direct visualization technology worldwide. Founded in 1999 and headquartered in Omer, Israel, it offers the Ultrasonic Surgical Endostapler and a complete endoscopic system for intraluminal treatment of gastroesophageal reflux disease. The system combines a miniature video camera, a surgical stapler, and ultrasonic alignment to enable a true partial anterior fundoplication without open or laparoscopic surgery. Medigus also designs and manufactures endoscopy systems for partners, providing the world’s smallest video cameras, processors, and a range of disposable endoscopes. The company focuses on innovative endoscopic procedures and aims to shift GERD treatment from surgery to endoluminal procedures.

Keystone Heart is a developer and manufacturer of medical devices focused on cerebral protection during cardiovascular procedures. The company specializes in creating innovative technologies designed to safeguard the brain from emboli, thereby reducing the risk of brain infarcts, strokes, neurocognitive decline, and dementia during procedures such as transcatheter aortic valve replacement and atrial fibrillation ablation. By prioritizing the preservation of cerebral function, Keystone Heart aims to enhance patient care and procedural success, enabling healthcare professionals to perform critical heart surgeries while minimizing potential adverse effects on brain health.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.